Publications

Image preview of Guide to Managing Colonoscopy Wait Time Indicator Performance resource

Guide to Managing Colonoscopy Wait Time Indicator Performance

November, 2019
This document supports endoscopy teams within district health boards (DHBs) to monitor and manage symptomatic and bowel screening colonoscopy-wait-time indicators (CWTIs) within clinically recommended timeframes. CWTIs provide a means of collecting information on how well DHBs are managing patient flow. To ensure all patients requiring diagnostic procedures are treated fairly and do not wait longer than maximum wait times, the Ministry has developed a dedicated framework for monitoring and managing symptomatic colonoscopy and bowel screening performance.

View publication:

Image preview of Interval Cancers in the Bowel Screening Pilot – Preliminary Report FIT negative resource

Interval Cancers in the Bowel Screening Pilot – Preliminary Report FIT negative

March, 2019
The report provides a preliminary analysis of interval cancers from the Bowel Screening Pilot (BSP) and early estimates of sensitivity. Interval cancers are cancers that are diagnosed between a negative (normal) screen and the time the next screen would have occurred. Sensitivity is the proportion of cancers in the screened population that are identified through screening. This report is preliminary as it is restricted to the first four years of the BSP and solely refers to interval cancers and sensitivity relating to the faecal immunochemical test (FIT) part of the screening pathway. It is also preliminary as it does not include interval cancers diagnosed following a negative diagnostic test (colonoscopy or computed tomographic (CT)-colonoscopy) undertaken in response to a positive FIT. Neither does the report include the stage or sight of the interval cancers. The report has been produced to share the information gathered to date in the spirit of transparency and open communication. However, caution is advised in drawing any strong conclusions from analysis due in part to the restrictions noted above but more importantly because the number of cancers identified to date is small.

View publication: